Clinical trials
Observational Hemophilia B trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Enrolling by invitation | 3 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
| Terminated | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novo Nordisk A/S | 6 |
| Swedish Orphan Biovitrum | 2 |
| Wyeth is now a wholly owned subsidiary of Pfizer | 2 |
| ApcinteX Ltd | 1 |
| CSL Behring | 1 |
| PedNet Haemophilia Research Foundation | 1 |
| Regeneron Pharmaceuticals | 1 |
| Royal Free Hospital NHS Foundation Trust | 1 |
| Spur Therapeutics | 1 |
| Ultragenyx Pharmaceutical Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemophilia B | 17 |
| Hemophilia A | 8 |
| Blood Coagulation Disorders | 2 |
| Hematologic Diseases | 2 |
| Blood Coagulation Disorders, Inherited | 1 |
| Coagulation Protein Disorders | 1 |
| Genetic Diseases, Inborn | 1 |
| Hemorrhagic Disorders | 1 |
| Hypersensitivity | 1 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.